A Study of SAR428926 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
To determine the maximum tolerated dose (MTD) of SAR428926 when administered as a single
agent in patients with advanced solid tumors.
To evaluate the anti-tumor response of SAR428926 when administered as a single agent in
patients with advanced triple negative breast cancer (TNBC) positive for the protein targeted
by SAR428926 To assess the preliminary anti-tumor response of SAR428926 when administered as
a single agent in patients with advanced solid tumors positive for the protein targeted by
SAR428926
Secondary Objectives:
To determine the overall safety profile of SAR428926 as a single agent. To characterize the
pharmacokinetics (PK) profile of SAR428926 and its metabolites.
To identify the recommended Phase 2 dose (RP2D) of SAR428926 as a single agent. To evaluate
the immunogenicity of SAR428926. To assess the tumor response and duration of tumor response
in all treated patients.
To evaluate the benefit of primary prophylaxis on the occurrence of corneal
(keratopathy/keratitis) toxicity (Expansion cohorts).